Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 41 of 41 entries
View as:

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT02180724 Org: User:
Start: 09/08/14 End: 12/31/26 Due: 12/31/27

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02180711 Org: User:
Start: 12/29/14 End: 12/29/28 Due: 12/29/29

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

Phase: N/A Priority: Normal
NCT ID: NCT02537444 Org: User:
Start: 11/30/15 End: 10/31/18 Due: 10/31/19

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

Phase: N/A Priority: Normal
NCT ID: NCT04914936 Org: User:
Start: 09/21/14 End: 10/16/14 Due: 10/16/15

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02211014 Org: User:
Start: 02/28/15 End: 04/26/19 Due: 04/26/20

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04867980 Org: User:
Start: 04/01/16 End: 05/09/16 Due: 05/09/17

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT02477696 Org: User:
Start: 07/28/15 End: 01/03/28 Due: 01/03/29

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Phase: N/A Priority: Normal
NCT ID: NCT03836261 Org: User:
Start: 02/25/19 End: 01/31/27 Due: 01/31/28

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

Phase: N/A Priority: Normal
NCT ID: NCT03527147 Org: User:
Start: 06/19/18 End: 03/31/21 Due: 03/31/22

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02570711 Org: User:
Start: 10/13/15 End: 04/30/16 Due: 04/30/17

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02029443 Org: User:
Start: 01/30/14 End: 09/06/27 Due: 09/06/28

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Phase: N/A Priority: Normal
NCT ID: NCT04529772 Org: User:
Start: 10/08/20 End: 02/05/27 Due: 02/05/28

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02717611 Org: User:
Start: 03/08/16 End: 09/06/26 Due: 09/06/27

A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04905043 Org: User:
Start: 06/03/16 End: 07/11/16 Due: 07/11/17

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT02387762 Org: User:
Start: 04/30/15 End: 06/30/16 Due: 06/30/17

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Phase: N/A Priority: Normal
NCT ID: NCT04876807 Org: User:
Start: 01/28/16 End: 03/15/16 Due: 03/15/17